Evaluation of CCL5 -403 G>A and CCR5 Δ32 gene polymorphisms in patients with breast cancer

Cancer Biomarkers

Volumn 14, Issue 5, 2014, Pages 343-351

  Eskandari Nasab, Ebrahim ^a,b   Hashemi, Mohammad ^b   Ebrahimi, Mahboubeh ^b   Amininia, Shadi ^b   Bahari, Gholamreza ^b   Mashhadi, Mohammad Ali ^b   Taheri, Mohsen ^b  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

breast cancer; CCL5; CCR5; gene polymorphism

Indexed keywords

BETA 2 MICROGLOBULIN; CHEMOKINE RECEPTOR CCR5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RANTES; CCL5 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; IRANIAN (CITIZEN); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; RISK; RISK FACTOR;

ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOKINE CCL5; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS;

EID: 84930732744     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140411     Document Type: Article

References (56)

1. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: A molecular target in breast cancer therapy. J Surg Res 2005;123: 158-69.
2. Turashvili G, Bouchal J, Burkadze G, Kolar Z. Differentiation of tumours of ductal and lobular origin: II. Genomics of invasive ductal and lobular breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149: 63-8.
3. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer-pilot study of 134 cases. PLoS One 2013;8: e53075.
4. Eskandari-Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, Moghaddam SS, et al. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep 2012;39: 10531-9.
5. Hashemi M, Eskandari-Nasab E, Fazaeli A, Rezaei H, Mash-hadi MA, Arbabi F, et al. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8-652 6N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene 2012;505: 176-9.
6. Hashemi M, Eskandari-Nasab E, Fazaeli A, Taheri M, Rezaei H, Mashhadi M, et al. Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark Med 2012;6: 797-803.
7. Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R. Breast cancer progression and host polymorphisms in the chemokine system: Role of the macrophage chemoattractant protein-1 (MCP-1)-2518 G allele. Clin Chem 2005;51: 452-5.
8. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66: 124-34.
9. Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: A focus on the interferon-gamma inducible chemokines and their receptor. Curr Pharm Des 2011;17: 3202-16.
10. Rotondi M, Lazzeri E, Romagnani P, Serio M. Role for interferon-gamma inducible chemokines in endocrine autoim-munity: An expanding field. J Endocrinol Invest 2003;26: 177-80.
11. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59: 4681-7.
12. Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, et al. Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: A case-control study. Hered Cancer Clin Pract 2012;10: 16.
13. Wigler N, Shina S, Kaplan O, Luboshits G, Chaitchik S, Key-dar I, et al. Breast carcinoma: A report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease. Isr Med Assoc J 2002;4: 940-3.
14. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adeno-carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15: 726-31.
15. Capoulade-Metay C, Ayouba A, Kfutwah A, Lole K, Petres S, Dudoit Y, et al. A natural CCL5/RANTES variant antagonist for CCR1 and CCR3. Immunogenetics 2006;58: 533-41.
16. Balistreri CR, Caruso C, Grimaldi MP, Listi F, Vasto S, Orlando V, et al. CCR5 receptor: Biologic and genetic implications in age-related diseases. Ann N Y Acad Sci 2007;1100: 162-72.
17. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shab-tai EL, Azenshtein E, et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 2006;12: 4474-80.
18. Velasco-Velazquez M, Pestell RG. The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013;2: e23660.
19. Zlotnik A. Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol 2006;13: 191-9.
20. Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, et al. Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 2009;15: 2647-56.
21. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27: 390-401.
22. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012;72: 3839-50.
23. Jeong KH, Moon JY, Chung JH, Kim YH, Lee TW. Significant associations between CCL5 gene polymorphisms and post-transplantational diabetes mellitus in Korean renal allo-graft recipients. Am J Nephrol 2010;32: 356-61.
24. Saenz-Lopez P, Carretero R, Cozar JM, Romero JM, Canton J, Vilchez JR, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer 2008;8: 382.
25. Liou JM, Lin JT, Huang SP, Wu CY, Wang HP, Lee YC, et al. RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol 2008;43: 115-23.
26. Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, et al. Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis. Cancer Epidemiol Biomarkers Prev 2011;20: 1439-46.
27. Weng CJ, Chien MH, Lin CW, Chung TT, Zavras AI, Tsai CM, et al. Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol 2010;46: 767-72.
28. Kwon KH, Lee YC, Chung JH, Eun YG. Association Study of Chemokine (C-C motif) Ligand 5 Gene Polymorphism and Papillary Thyroid Cancer. J Invest Surg 2013.
29. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009;23: 429-35.
30. Guleria K, Sharma S, Manjari M, Uppal MS, Singh NR, Sam-byal V. p.R72P, PIN3 Ins16bp polymorphisms of TP53 and CCR5?32 in north Indian breast cancer patients. Asian Pac J Cancer Prev 2012;13: 3305-11.
31. Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: Associated with gallbladder cancer susceptibility. Scand J Immunol 2008;67: 516-22.
32. Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol 2012;31: 1418-24.
33. Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: Association with early stage of cervical cancer. Oncol Res 2008;17: 87-91.
34. Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, et al. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: A prospective study. Eur J Gastroenterol Hepatol 2007;19: 425-31.
35. Kucukgergin C, Isman FK, Dasdemir S, Cakmakoglu B, Sanli O, Gokkusu C, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopatho-logical characteristics of bladder cancer. Gene 2012;511: 7-11.
36. Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 2009;74: 414-8.
37. Hashemi M, Eskandari-Nasab E, Fazaeli A, Bahari A, Hashemzehi NA, Shafieipour S, et al. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTT1, GSTM1, and GSTP1) and susceptibility to nonalcoholic fatty liver disease in Zahedan, Southeast Iran. DNA Cell Biol 2012;31: 672-7.
38. Eskandari-Nasab E, Moghadampour M, Hasani SS, Hadadi-Fishani M, Mirghanizadeh-Bafghi SA, Asadi-Saghandi A, et al. Relationship between IFN-gamma gene polymorphisms and susceptibility to brucellosis infection. Microbiol Immunol 2013.
39. Rezaeifar A, Eskandari-Nasab E, Moghadampour M, Kharazi-Nejad E, Hasani SS, Asadi-Saghandi A, et al. The association of interleukin-18 promoter polymorphisms and serum levels with duodenal ulcer, and their correlations with bacterial CagA and VacA virulence factors. Scand J Infect Dis 2013;45: 584-92.
40. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194: 926-30.
41. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: A web tool for the analysis of association studies. Bioinformat-ics 2006;22: 1928-9.
42. Lewontin RC. The detection of linkage disequilibrium in molecular sequence data. Genetics 1995;140: 377-88.
43. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 2009;29: 313-26.
44. Wang J, He Q, Shao YG, Ji M. Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci 2013;17: 596-608.
45. Rose CE, Jr., Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 2003;10: 273-88.
46. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198: 1381-9.
47. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62: 1093-102.
48. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007;9: R15.
49. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: Identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10: 6789-95.
50. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proud-foot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63: 8360-5.
51. Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R, et al. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci 2012;103: 904-12.
52. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449: 557-63.
53. Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 2008;14: 45-50.
54. Schimanski CC, Moehler M, Gockel I, Zimmermann T, Lang H, Galle PR, et al. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. J Cancer Res Clin Oncol 2011;137: 1139-45.
55. Ugurel S, Schrama D, Keller G, Schadendorf D, Brocker EB, Houben R, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving im-munotherapy. Cancer Immunol Immunother 2008;57: 685-91.
56. Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011;71: 5455-66.